

14 Jun 2019 | News

QUOTED. 14 June 2019. Ryan Walters.

by

Biotronik SE & Co. KG believes the unique features of its new lines of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators set it apart from bigger rivals. See what Biotronik's president Ryan Walters said about it here.

“We continue to receive positive feedback on acute advantages like ease of insertion and improved patient comfort. The impact is immediate and the distinct advantages of the Acticor and Rivacor devices continue on with benefits like extended battery longevity and enhanced diagnostics.” – Ryan Walters, president, Biotronik, Inc.

- Find out more: [*Biotronik Addresses US CRM Market With Rivacor And Acticor, The Most Comfortable ICDs*](#)

[*Click here*](#) for a free trial of *Medtech Insight*